Neonc Technologies (NASDAQ:NTHI – Get Free Report) is expected to post its results before the market opens on Friday, February 20th. Analysts expect Neonc Technologies to post earnings of ($0.37) per share for the quarter.
Neonc Technologies Price Performance
NASDAQ:NTHI opened at $9.26 on Wednesday. The stock has a 50-day simple moving average of $9.10 and a two-hundred day simple moving average of $8.87. Neonc Technologies has a 52-week low of $3.20 and a 52-week high of $25.00.
Insider Buying and Selling at Neonc Technologies
In other news, President Amir F. Heshmatpour bought 24,000 shares of Neonc Technologies stock in a transaction dated Friday, November 21st. The shares were purchased at an average cost of $6.07 per share, with a total value of $145,680.00. Following the completion of the acquisition, the president owned 2,986,000 shares of the company’s stock, valued at $18,125,020. This trade represents a 0.81% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders bought a total of 31,100 shares of company stock worth $192,099 in the last ninety days.
Hedge Funds Weigh In On Neonc Technologies
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on NTHI. Weiss Ratings reiterated a “sell (e+)” rating on shares of Neonc Technologies in a research note on Monday, December 29th. Zacks Research upgraded shares of Neonc Technologies to a “hold” rating in a research report on Wednesday, January 14th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Reduce”.
Get Our Latest Stock Report on NTHI
About Neonc Technologies
Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Read More
- Five stocks we like better than Neonc Technologies
- Energy Security Is Now National Security – Positioning Is Happening Now
- Why Q4 Could Destroy Your Wealth
- Gold Is About to Do Something It Hasn’t in 90 Years
- 3 Signs You May Want to Switch Financial Advisors
- When to buy gold (mathematically)
Receive News & Ratings for Neonc Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neonc Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
